From: Prognostic and predictive biomarker developments in multiple myeloma
Result | Criteria definitiona |
---|---|
Sustained MRD negative | MRD negativity in the marrow (NGF or NGS, or both) and by imaging as defined below, confirmed minimum of 1Â year apart. Subsequent evaluations can be used to additionally specify the duration of negativity (e.g. MRD negative at 5Â years) |
Flow MRD negative | Absence of phenotypically aberrant clonal plasma cells by NGF on bone marrow aspirates using the EuroFlow standard operation procedure for MRD detection in multiple myeloma (or validated equivalent method) with a minimum sensitivity of 1 in 105 or greater nucleated cells |
Sequencing MRD negative | Absence of clonal plasma cells by NGS on bone marrow aspirate in which presence of a clone is defined as fewer than two identical sequencing reads obtained after DNA sequencing of bone marrow aspirates with the LymphoSIGHT platform (or validated equivalent method), with a minimum sensitivity of 1 in 105 or greater nucleated cells |
Imaging plus MRD negative | MRD negativity as defined by NGF or NGS plus disappearance of every area of increased tracer uptake found at baseline or a preceding PET/CT or decrease to less than mediastinal blood pool SUV or decrease to less than that of surrounding normal tissue |